Patents Examined by Bao Q Li
-
Patent number: 12036278Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.Type: GrantFiled: January 30, 2023Date of Patent: July 16, 2024Assignee: Calidi Biotherapeutics (Nevada), Inc.Inventors: Aladar Szalay, Boris Minev
-
Patent number: 12038445Abstract: The present invention provides biomarker and biomarker panels useful for diagnostic methods evaluating liver disease status in a subject, monitoring liver disease, distinguishing between liver diseases, treating subjects evaluated by diagnostic methods of the invention, providing diagnostic tests for evaluating liver disease status in a subject, and kits there for.Type: GrantFiled: May 30, 2017Date of Patent: July 16, 2024Assignee: HUMAN METABOLOMICS INSTITUTE, INC.Inventor: Wei Jia
-
Patent number: 12031978Abstract: A method for determining a susceptibility of a patient to infection by SARS-CoV-2 virus includes obtaining a tissue sample from the patient. The method also includes obtaining first cells from the tissue sample. The method further includes adding the first cells to second cells infected with the SARS-CoV-2 virus. Moreover, the method includes measuring a property of the second cells related to death of the second cells after adding the first cells to the second cells. In addition, the method includes calculating a susceptibility of the patient to infection by the SARS-CoV-2 virus using at least the property of the second cells.Type: GrantFiled: August 24, 2021Date of Patent: July 9, 2024Inventor: Aurangzeb Nafees Nagy
-
Patent number: 12030944Abstract: Methods are provided for targeting cells for depletion, including without limitation tumor cells, in a regimen comprising contacting the targeted cells with a combination of agents that modulate immunoregulatory signaling. Immunoregulatory modulating agents include (i) an agent that blockades CD47 activity; and (ii) an agent that agonizes an immune costimulatory molecule, e.g. CD137. The regimen may further comprise an agent that specifically binds to the target cell, e.g. an antibody or biologically active fragment or derivative thereof. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single immunoregulatory modulating agent is used; and the effect may be synergistic relative to a regimen in which a single immunoregulatory modulating agent is used.Type: GrantFiled: February 16, 2023Date of Patent: July 9, 2024Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Peter Schnorr, Akanksha Chhabra, Judith A. Shizuru, Irving L. Weissman, Kipp Andrew Weiskopf
-
Patent number: 12024552Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.Type: GrantFiled: August 14, 2020Date of Patent: July 2, 2024Assignee: VISTERRA, INC.Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
-
Patent number: 12023373Abstract: Disclosed are immunization antigens that have been glyco-engineered to include non-native glycosylation patterns with a view to enhance their properties as antigens for use in such areas as vaccination and antibody production. Also disclosed are to means and methods for producing the glycomodified antigens as well of methods and uses of the glycomodified antigens.Type: GrantFiled: January 10, 2020Date of Patent: July 2, 2024Assignee: EXPRES2ION BIOTECHNOLOGIES APSInventors: Stine Broch Clemmensen, Teit Max Moscote Søgaard, Willem Adriaan De Jongh
-
Patent number: 12024724Abstract: The present invention relates to an oncolytic virus which is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and/or at a lower dose in vitro than one or more of the other clinical isolates in the panel.Type: GrantFiled: August 4, 2022Date of Patent: July 2, 2024Assignee: Replimune LimitedInventor: Robert Coffin
-
Patent number: 12016920Abstract: Provided are an adjuvant useful for preparing a vaccine having high efficacy and high safety, and a vaccine composition comprising the adjuvant. The adjuvant comprises a peptide nucleic acid to which a cell penetrating peptide is bound.Type: GrantFiled: June 5, 2020Date of Patent: June 25, 2024Assignee: DENKA COMPANY LIMITEDInventors: Ryotaro Mitsumata, Asumi Kanda
-
Patent number: 12016910Abstract: The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides antigenic peptides, which are distinct from, but have amino acid similarity to, fragments of human tumor antigens. The present invention further provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.Type: GrantFiled: April 11, 2019Date of Patent: June 25, 2024Assignee: ENTEROME S.A.Inventors: Laurent Chene, Christophe Bonny, Francesco Strozzi
-
Patent number: 12005104Abstract: The invention relates to the field of cancer, in particular colorectal cancer. In particular, it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the APC, ARID1A, KMT2D, RNF43, SOX9, TCF7L2, TP53, and ZFP36L2 genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.Type: GrantFiled: July 25, 2019Date of Patent: June 11, 2024Assignee: CureVac Netherlands B.V.Inventor: Ronald Hans Anton Plasterk
-
Patent number: 11981923Abstract: The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.Type: GrantFiled: April 18, 2022Date of Patent: May 14, 2024Assignee: Baylor College of MedicineInventors: Ann Marie Leen, Juan Fernando Vera Valdes, Cliona M. Rooney, Ulrike Gerdemann
-
Patent number: 11975057Abstract: The present invention provides compositions for treating or preventing cancer and methods of using and making the compositions. The compositions comprise herpes simplex viruses comprising recombinant herpes simplex virus genomes. Further provided are recombinant herpes simplex virus genomes, viruses comprising the recombinant herpes simplex virus genomes, and cancer vaccines and other compositions comprising the viruses.Type: GrantFiled: August 1, 2019Date of Patent: May 7, 2024Assignee: Board of Supervisors of Louisiana State University Agriculture and Mechanical CollegeInventors: Konstantin G. Kousoulas, Vladimir N. Chouljenko, James Michael Mathis
-
Patent number: 11976338Abstract: Provided are a method of manufacturing a coronavirus diagnostic kit, which includes preparing a one-component primer/probe mixture by mixing a primer set including a primer pair consisting of base sequences of SEQ ID NOs: 1 and 2, a primer pair consisting of base sequences of SEQ ID NOs: 3 and 4, a primer pair consisting of base sequences of SEQ ID NOs: 5 and 6, and a primer pair consisting of base sequences of SEQ ID NOs: 7 and 8; and a probe consisting of a base sequence of SEQ ID NO: 9, a probe consisting of a base sequence of SEQ ID NO: 10, a probe consisting of a base sequence of SEQ ID NO: 11, and a probe consisting of a base sequence of SEQ ID NO: 12, a coronavirus diagnostic kit manufactured using the same, and a method of diagnosing coronavirus using the same.Type: GrantFiled: April 22, 2020Date of Patent: May 7, 2024Assignee: OSANG HEALTHCARE CO., LTD.Inventors: Joo Hyung Kim, Go Woon Cha
-
Patent number: 11965218Abstract: The present disclosure concerns methods of detecting viral respiratory infections by analyzing biomarkers in a viral transport medium sample. In various embodiments the biomarkers are assessed by measuring mRNA or protein. In certain embodiments the biomarkers are nasal-virus induced molecules.Type: GrantFiled: October 11, 2017Date of Patent: April 23, 2024Assignee: YALE UNIVERSITYInventors: Ellen Foxman, Marie Landry
-
Patent number: 11957749Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.Type: GrantFiled: December 14, 2018Date of Patent: April 16, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Virginia Ammendola, Babak Bayat, Clarisse Lorin, Ventzislav Bojidarov Vassilev, Alessandra Vitelli
-
Patent number: 11952406Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.Type: GrantFiled: June 2, 2023Date of Patent: April 9, 2024Assignee: OTHAIR PROTHENA LIMITEDInventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
-
Patent number: 11945855Abstract: Recombinant polypeptides comprising a modified DR?1 domain are provided. In some embodiments, the polypeptides include the modified DR?1 domain, an antigenic peptide, and optionally a linker sequence. Pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said recombinant polypeptides or pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides are also provided.Type: GrantFiled: October 4, 2019Date of Patent: April 2, 2024Assignees: Oregon Health & Science University, The United States Government as represented by the Department of Veterans AffairsInventors: Roberto Meza-Romero, Arthur A. Vandenbark, Halina Offner
-
Patent number: 11944677Abstract: This invention relates to chimeric virus-like particles (VLPs) assembled from a polypeptide comprising a papilloma virus (PV) L1 protein or L1/L2 protein and a target peptide comprising a CD8+ T cell epitope derived from a human pathogen. This invention also relates to methods using the chimeric VLPs as antigen-specific redirectors of immune responses.Type: GrantFiled: March 25, 2022Date of Patent: April 2, 2024Assignee: VERIMMUNE INC.Inventors: Joshua Weiyuan Wang, Nattha Ingavat
-
Patent number: 11921114Abstract: Alternative antibodies to screen for SARS-CoV-2 are disclosed. One alternative antibody is Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1056 (“E3-Antibody” or “E3”), from EastCoast Bio, Inc., PO Box 489, North Berwick, ME 03906, USA (“EastCoast Bio”). Another alternative antibody is a combination of the E3-Antibody and Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1057 (“E1-Antibody” or “E1”), from EastCoast Bio (the combination of the E1-Antibody and the E3-Antibody is designated as “E1/E3-Antibody” or simply “E1/E3”).Type: GrantFiled: June 2, 2021Date of Patent: March 5, 2024Inventors: Melicia R. Gainey, Dalia Natour
-
Patent number: 11896666Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.Type: GrantFiled: March 8, 2021Date of Patent: February 13, 2024Assignee: Zoetis Services LLCInventors: Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, Jr., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi